ArticleCancer diagnosis & prognosis

NSCLC Patients Achieving Long-term Progression-free Survival With Docetaxel Plus Ramucirumab: A Retrospective Study.

Kunihiko Miyazaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.